Sodium Bicarbonate
Brand names: Sodium Bicarbonate (generic)
Sodium bicarbonate is an alkalinising agent; in urology oral sodium bicarbonate is used to alkalinise the urine, for example to ease the discomfort of lower urinary tract infection and in the prevention and treatment of uric acid and cystine stones, and to manage chronic metabolic acidosis in chronic kidney disease.
The product information we hold does not support a dose for this page's specific use, route or population, so none is shown. Follow your local or national guideline, and confirm against the product SmPC.
The licensed dosing — for the medicine's licensed uses, which may differ from this page's — is on Sodium Bicarbonate.
Clinical monograph
How it works
It provides bicarbonate that buffers hydrogen ions, raising blood and urinary pH; the more alkaline urine increases the solubility of uric acid and cystine, reducing crystallisation.
Prescribing in practice
- The sodium load can cause fluid retention and worsen hypertension or heart failure, and may cause hypokalaemia and metabolic alkalosis, so use cautiously where sodium must be restricted and monitor accordingly.
- It can alter the renal handling and effectiveness of some medicines through changes in urinary pH, so review concurrent drug therapy.
- Target the urinary pH appropriate to the indication when used for stone prevention to avoid over-alkalinisation, which can promote calcium phosphate stones.
Monitoring
Monitor urinary pH for stone or UTI indications, alongside electrolytes, bicarbonate, blood pressure and fluid status.
Counselling the patient
- Maintain a good fluid intake, particularly when used to help prevent stones.
- Report ankle swelling, breathlessness or muscle weakness, which may indicate fluid or salt imbalance.
Evidence & guidelines
Urinary alkalinisation with sodium bicarbonate is established for uric acid and cystine stone management and for symptomatic relief, and oral bicarbonate is supported by guidance for metabolic acidosis in CKD.
Reference: EAU Urolithiasis Guidelines 2024; AUA Stone Disease Guidelines 2019; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.